Michael Atkins, MD
The combination of frontline atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated superior efficacy compared with sunitinib (Sutent) or atezolizumab monotherapy in patients with advanced renal cell carcinoma (RCC), according to findings from the phase II IMmotion150 study
The ongoing phase III IMmotion151 trial is comparing frontline atezolizumab/bevacizumab with sunitinib in patients with advanced RCC (NCT02420821).
Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 35, 2017 (suppl; abstr 4505).
... to read the full story